The expanded approval offers a significant boost for Jardiance, sales of which are already on track to top $1 billion this year. In the second quarter, revenue from the drug jumped 36% to about $357 million.
Lilly and Boehringer next have their eyes on approval for heart failure patients with preserved ejection fraction. The harder-to-treat condition occurs when the left ventricle can’t properly relax, resulting in the heart being unable to fill with enough blood to pump out to the body even though it’s still contracting normally.
